Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329379 | 0.84 | — | — | |
| SCHEMBL6390852 | 0.82 | TTR (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL28964474 | 0.82 | RAB9A (0.34) | ALDH1A1 | |
| SCHEMBL15345322 | 0.78 | POLB (0.49) | ALDH1A1 | |
| SCHEMBL17850514 | 0.71 | PKLR (0.38) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL329373 | 0.71 | — | — | |
| SCHEMBL5187557 | 0.69 | HTR6 (0.36) | TRPV4 | |
| SCHEMBL11140317 | 0.69 | ELANE (0.42) | ALDH1A1 | |
| SCHEMBL4786286 | 0.68 | TDP1 (0.37) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL2574655 | 0.67 | HSD17B10 (0.36) | ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008115259-A2 | DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1758873-A1 | UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006002284-A1 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282818-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-1432696-A1 | CHROMAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1406884-A1 | ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003029238-A1 | CHROMAN DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002092585-A1 | NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282818-A1 | Ubiquitin ligase inhibitors | NEDD4, TRAF6, XIAP | ALDH1A1 2627/4885HSD17B10 3794/4885TDP1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.